ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SLRX Salarius Pharmaceuticals Inc

0.5276
-0.0087 (-1.62%)
After Hours
Last Updated: 15:40:04
Delayed by 15 minutes

Period:

Draw Mode:

Volume 97,758
Bid Price 0.4903
Ask Price 0.53
News -
Day High 0.5325

Low
0.43

52 Week Range

High
2.31

Day Low 0.481
Share Name Share Symbol Market Stock Type
Salarius Pharmaceuticals Inc SLRX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0087 -1.62% 0.5276 15:40:04
Open Price Low Price High Price Close Price Previous Close
0.501 0.481 0.5325 0.5276 0.5363
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
211 97,758 US$ 0.4968163 US$ 48,568 - 0.43 - 2.31
Last Trade Type Quantity Price Currency
16:18:35 1 US$ 0.53 USD

Salarius Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.09M 3.94M - 0 -12.54M -3.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Salarius Pharmaceuticals News

Date Time Source News Article
3/22/202415:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full..
3/06/202415:02Edgar (US Regulatory)Form 8-K - Current report
2/22/202415:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202415:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202415:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202407:00GlobeNewswire Inc.Salarius Provides Update on Strategic Review Process and..
1/16/202407:00GlobeNewswire Inc.Salarius Pharmaceuticals Issued U.S. Patent for..
1/03/202407:30GlobeNewswire Inc.Investigator-initiated Phase 1/2 Clinical Trial Using..
11/09/202316:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/202307:30GlobeNewswire Inc.Salarius Completes FDA Type B Meeting for Seclidemstat Ewing..
10/27/202314:57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial..
9/06/202316:09Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SLRX Message Board. Create One! See More Posts on SLRX Message Board See More Message Board Posts

Historical SLRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.5050.54320.46520.517609513,7590.02264.48%
1 Month0.49260.560.45120.499310527,2270.0357.11%
3 Months0.56280.78880.430.5361713118,548-0.0352-6.25%
6 Months0.76170.930.430.566012273,114-0.2341-30.73%
1 Year1.792.310.430.956583878,625-1.26-70.53%
3 Years31.7537.750.4317.06504,485-31.22-98.34%
5 Years288.75370.3850.4328.63570,666-288.22-99.82%

Salarius Pharmaceuticals Description

Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Your Recent History

Delayed Upgrade Clock